These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31835085)

  • 1. The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.
    Aboalsoud A; El-Ghaiesh SH; Abd Elmonem FF; Salem ML; Abdel Rahman MN
    Int Immunopharmacol; 2020 Jan; 78():106068. PubMed ID: 31835085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
    Ma M; Wang X; Liu N; Shan F; Feng Y
    Int Immunopharmacol; 2020 Jun; 83():106388. PubMed ID: 32171145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms.
    Gaballah HH; Gaber RA; Mohamed DA
    Toxicol Appl Pharmacol; 2017 Feb; 316():27-35. PubMed ID: 28025107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin and 5-flurouracil act synergistically to induce cellular weapons in experimentally induced Solid Ehrlich Carcinoma: Realistic role of P53; a guardian fights in a cellular battle.
    Soliman NA; Abd-Ellatif RN; ELSaadany AA; Shalaby SM; Bedeer AE
    Chem Biol Interact; 2019 Sep; 310():108740. PubMed ID: 31288002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.
    Liu N; Ma M; Qu N; Wang R; Chen H; Hu F; Gao S; Shan F
    Int Immunopharmacol; 2020 Sep; 86():106718. PubMed ID: 32585612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
    McLaughlin PJ; Rogosnitzky M; Zagon IS
    Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
    El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
    Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice.
    Ibrahim HM; Abdel Ghaffar FR; El-Elaimy IA; Gouida MS; Abd El Latif HM
    Biomed Pharmacother; 2018 Oct; 106():43-49. PubMed ID: 29945116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent blockade of OGFr and treatment of autoimmune disorders.
    Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1323-1330. PubMed ID: 30541348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.
    El-Sisi AE; Sokkar SS; Ibrahim HA; Hamed MF; Abu-Risha SE
    Fundam Clin Pharmacol; 2020 Aug; 34(4):458-475. PubMed ID: 32080901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
    McLaughlin PJ; Zagon IS
    Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
    Zagon IS; Porterfield NK; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.